<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539561</url>
  </required_header>
  <id_info>
    <org_study_id>Focus-PiQo4 Pigmentation-19-02</org_study_id>
    <nct_id>NCT04539561</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of PiQo4 for the Treatment of Hand Pigmentation Using 1064nm PSL and 532nm PSL</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of PiQo4 for the Treatment of Hand Pigmentation Using 1064nm PSL and 532nm PSL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Focus Medical, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Focus Medical, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 20 healthy subjects at a single site, aged 21-70 years old with congenital or&#xD;
      acquired challenging/resistant, age/sun-related flat and benign hand pigmentation who wish to&#xD;
      improve their skin appearance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hands pigmentation change assessed by investigator</measure>
    <time_frame>1 month follow up</time_frame>
    <description>Hands pigmentation change assessed by investigator at the 1 month follow up using the 5-point Pigment Improvement Score where score of between 0 and 4 will be assigned (0- No improvement in pigmentation, 1- Trace to mild improvement of some lesions, 2- Moderate response: some lesions lighter, 3- Good response: most lesions much lighter and 4- Excellent response- Most or all lesions much lighter or gone.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pigmentation</condition>
  <arm_group>
    <arm_group_label>Pigmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of Hand Pigmentation Using PiQo4 Laser System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PiQo4 Laser System</intervention_name>
    <description>PiQo4 Laser System for treatment of hand pigmentation</description>
    <arm_group_label>Pigmentation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Female/Male.&#xD;
&#xD;
          -  Age= 21-70 (Adults).&#xD;
&#xD;
          -  Fitzpatrick skin phototype = I-V&#xD;
&#xD;
          -  Congenital or acquired benign pigmentation on hands.&#xD;
&#xD;
          -  Presence of at least three (3) lesions with similar pigmentation intensity in the&#xD;
             treatment area in diameters larger than 2 mm.&#xD;
&#xD;
          -  Able to read, understand and provide written Informed Consent.&#xD;
&#xD;
          -  Able and willing to comply with the treatment/follow-up schedule and requirements.&#xD;
&#xD;
          -  Women of child-bearing potential are required to use a reliable method of birth&#xD;
             control (such as an intrauterine device, birth control pills, condom with spermicidal,&#xD;
             NuvaRing, partner with vasectomy, Implanon or other FDA-approved devices, or&#xD;
             abstinence) during the course of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of post inflammatory pigmentary disorders, particularly a tendency for hyper-&#xD;
             or hypo-pigmentation.&#xD;
&#xD;
          -  Tanning (artificial or natural) 1 month prior first treatment and during the entire&#xD;
             study duration including follow-up.&#xD;
&#xD;
          -  Excessive underlying vascular conditions (e.g. dense network of capillaries).&#xD;
&#xD;
          -  Pregnant, intending to become pregnant during the course of study, less than 3 months&#xD;
             postpartum or less than 3 months after completion of breastfeeding.&#xD;
&#xD;
          -  Prior skin laser, light or other energy device treatment in treated area within 6&#xD;
             months of initial treatment or during the course of the study.&#xD;
&#xD;
          -  Prior ablative resurfacing procedure in treated area with laser or other devices&#xD;
             within 12 months of initial treatment or during the course of the study.&#xD;
&#xD;
          -  Prior treatment with medium-depth or deeper, chemical peels or dermabrasion in treated&#xD;
             area within 3 months of initial treatment or during the course of the study.&#xD;
&#xD;
          -  Any other surgery in treated area within 9 months of initial treatment or during the&#xD;
             course of the study.&#xD;
&#xD;
          -  Hypersensitive to light exposure or the use of photosensitive medication for which&#xD;
             light exposure is contraindicated.&#xD;
&#xD;
          -  Multiple dysplastic nevi or suspicious pigmentation in area to be treated.&#xD;
&#xD;
          -  Presence of underlying tattoo in the treatment area.&#xD;
&#xD;
          -  Significant concurrent illness (e.g. uncontrolled diabetes) or any disease state that&#xD;
             in the opinion of the Investigator would interfere with the treatment or healing&#xD;
             process.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Firas Al-Niaimi, MD</last_name>
    <phone>+447956147543</phone>
    <email>Firas55@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>&quot;Sk;N&quot; Clinic</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Firas Al-Niaimi, Dr.</last_name>
      <phone>+447956147543</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

